| Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia (NCT00802100) | National Institute of Mental Health (NIMH) | 2008-12-01 |
| A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone (NCT01979679) | University of California, Irvine | 2008-12-01 |
| Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia (NCT00712660) | Prague Psychiatric Center | 2008-11-01 |
| Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy (NCT00791440) | New York State Psychiatric Institute | 2008-11-01 |
| Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia (NCT00768612) | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-11-01 |
| Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients (NCT01300637) | Taipei Medical University WanFang Hospital | 2008-11-01 |
| Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia (NCT00810667) | H. Lundbeck A/S | 2008-11-01 |
| Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse (NCT00798109) | Assistance Publique - Hôpitaux de Paris | 2008-11-01 |
| Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia (NCT00827840) | Chonnam National University Hospital | 2008-11-01 |
| Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia (NCT01300364) | Fundació Sant Joan de Déu | 2008-11-01 |
| The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics (NCT02142556) | Tri-Service General Hospital (TSGH) | 2008-11-01 |
| Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia (NCT00875498) | Hôpital le Vinatier | 2008-11-01 |
| A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia (NCT00888693) | AbbVie | 2008-11-01 |
| Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) (NCT00779506) | AstraZeneca | 2008-11-01 |
| An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia (NCT00728195) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-11-01 |
| Four Dimensions in Schizophrenia (NCT00782899) | AstraZeneca | 2008-10-01 |
| Transcranial Magnetic Stimulation (TMS) in Schizophrenia (NCT00564096) | BeerYaakov Mental Health Center | 2008-10-01 |
| Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED) (NCT00848484) | Merck Sharp & Dohme LLC | 2008-10-01 |
| fMRI Cholinergic Mechanisms in Schizophrenia (NCT01191827) | US Department of Veterans Affairs | 2008-10-01 |
| General Practice Research Database Seroquel XR Safety Study (NCT01447082) | AstraZeneca | 2008-10-01 |
| Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone (NCT00480844) | Sheba Medical Center | 2008-10-01 |
| Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects (NCT00815854) | University of Michigan | 2008-10-01 |
| Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia (NCT00770237) | University of Maryland, Baltimore | 2008-10-01 |
| Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. (NCT00790192) | Sumitomo Pharma America, Inc. | 2008-10-01 |
| Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies (NCT00937716) | University of Alabama at Birmingham | 2008-10-01 |
| Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up (NCT02526030) | Fundación Marques de Valdecilla | 2008-10-01 |
| Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia (NCT00757497) | National Institute of Mental Health (NIMH) | 2008-09-17 |
| Digoxin Drug-Drug Interaction With Lurasidone HCl (NCT01082289) | Sumitomo Pharma America, Inc. | 2008-09-01 |
| Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia (NCT00772005) | Cephalon | 2008-09-01 |
| Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia (NCT01391403) | Beijing HuiLongGuan Hospital | 2008-09-01 |
| Efficacy Study on Cognitive Functions in Schizophrenic Patients (NCT00761670) | Sanofi | 2008-09-01 |
| Standard Comprehensive Intervention to Treat First-episode Schizophrenia (NCT01057849) | Peking University | 2008-09-01 |
| A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation (NCT00723606) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2008-09-01 |
| Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (NCT00706654) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2008-09-01 |
| Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors (NCT00802919) | Nathan Kline Institute for Psychiatric Research | 2008-09-01 |
| Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects (NCT00734435) | Orexigen Therapeutics, Inc | 2008-09-01 |
| Cognitive Functioning Related to Job Tenure Among Patients With Schizophrenia (NCT00838123) | Far Eastern Memorial Hospital | 2008-08-01 |
| Lithium Drug-Drug Interaction Study With Lurasidone HCl (NCT01074073) | Sumitomo Pharma America, Inc. | 2008-08-01 |
| A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence (NCT00737256) | Paul Saenger | 2008-08-01 |
| Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia (NCT00859872) | Central South University | 2008-08-01 |
| Social Functioning in Schizophrenia (NCT00814996) | Far Eastern Memorial Hospital | 2008-08-01 |
| Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR (NCT00750087) | AstraZeneca | 2008-08-01 |
| Artemisinin to Reduce The Symptoms of Schizophrenia (NCT00753506) | Sheppard Pratt Health System | 2008-08-01 |
| Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness (NCT00714818) | University of British Columbia | 2008-08-01 |
| A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients (NCT00725855) | Memory Pharmaceuticals | 2008-08-01 |
| Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (NCT00705783) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2008-07-01 |
| Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia (NCT00727103) | State University of New York - Upstate Medical University | 2008-07-01 |
| A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia (NCT01812642) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-07-01 |
| Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER) (NCT01577186) | Johnson & Johnson Taiwan Ltd | 2008-07-01 |
| Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia (NCT00789906) | BeerYaakov Mental Health Center | 2008-07-01 |
| Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia (NCT00749970) | AstraZeneca | 2008-07-01 |
| Schizophrenic Patients in Integrated Care (NCT00681629) | AstraZeneca | 2008-07-01 |
| Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain (NCT00709202) | Nathan Kline Institute for Psychiatric Research | 2008-07-01 |
| Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study (NCT00708396) | BeerYaakov Mental Health Center | 2008-07-01 |
| The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia (NCT02021201) | Birte Glenthoj | 2008-07-01 |
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study (NCT00567710) | BioLineRx, Ltd. | 2008-07-01 |
| A Study of a Remediation Program of Social Cognition in Schizophrenia (NCT01077791) | Assistance Publique - Hôpitaux de Paris | 2008-07-01 |
| Nicotine Effects on Endophenotypes of Schizophrenia (NCT01315002) | University Hospital, Bonn | 2008-07-01 |
| Functional Rehabilitation for Older Patients With Schizophrenia (NCT00712075) | US Department of Veterans Affairs | 2008-07-01 |
| Impact of Genetic Counseling for Individuals With Mental Illness (NCT00713804) | University of British Columbia | 2008-07-01 |
| A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam. (NCT00929370) | GlaxoSmithKline | 2008-07-01 |
| A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia (NCT01541371) | Xian-Janssen Pharmaceutical Ltd. | 2008-07-01 |
| The Bioequivalence Of Two Different Lurasidone Formulations In Patients (NCT01082250) | Sumitomo Pharma America, Inc. | 2008-07-01 |
| Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia (NCT00711269) | Sumitomo Pharma Co., Ltd. | 2008-06-27 |
| Efficacy of Bifeprunox in Patients With Schizophrenia (NCT00704509) | H. Lundbeck A/S | 2008-06-01 |
| Tolerability, Safety and Efficacy of the H1-coil Deep Transcranial Magnetic Stimulation in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia (NCT00685321) | Shalvata Mental Health Center | 2008-06-01 |
| Study to Demonstrate Cognitive Enhancing Effects of BF2.649 (NCT00690274) | University of Texas Southwestern Medical Center | 2008-06-01 |
| Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 (NCT00722176) | BioLineRx, Ltd. | 2008-06-01 |
| Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics (NCT00696813) | Janssen-Cilag International NV | 2008-06-01 |
| Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT) (NCT00753051) | Khon Kaen University | 2008-06-01 |
| Cognitive Behavioral Social Skills Training for Patients With Late-Life Schizophrenia: a Pilot Study (NCT00832845) | Centre for Addiction and Mental Health | 2008-06-01 |
| Biomarker Study of Acamprosate in Schizophrenia (NCT00688324) | University of Maryland, Baltimore | 2008-06-01 |
| Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time. (NCT00945503) | GlaxoSmithKline | 2008-05-19 |
| Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families (NCT00924976) | University of North Carolina, Chapel Hill | 2008-05-01 |
| Modafinil Effects on Cognition in Schizophrenia Patients (NCT00711464) | University of California, Los Angeles | 2008-05-01 |
| A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses (NCT00701753) | TheraGenetics Limited | 2008-05-01 |
| A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia (NCT01577160) | Johnson & Johnson Taiwan Ltd | 2008-05-01 |
| The Effect of Intranasal Administration of Oxytocin on Empathic Abilities. (NCT00813436) | Shalvata Mental Health Center | 2008-05-01 |
| A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine (NCT01015001) | Hospital de Clinicas de Porto Alegre | 2008-05-01 |
| A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia (NCT00686400) | Martin-Luther-Universität Halle-Wittenberg | 2008-05-01 |
| Metformin for Weight Loss in Schizophrenia (NCT01177709) | Nathan Kline Institute for Psychiatric Research | 2008-05-01 |
| Cognitive Training to Enhance VA Work Program Outcomes (NCT00829400) | VA Connecticut Healthcare System | 2008-05-01 |
| Sodium Oxybate in Schizophrenia With Insomnia (NCT00594256) | Nathan Kline Institute for Psychiatric Research | 2008-05-01 |
| Phase IIA Study in Patients With Schizophrenia (NCT00686998) | AstraZeneca | 2008-05-01 |
| Cognitive Training to Improve Work Outcomes in Severe Mental Illness (NCT00895258) | University of California, San Diego | 2008-04-01 |
| Acceptance and Commitment Therapy for Delusions (NCT00657631) | Weill Medical College of Cornell University | 2008-04-01 |
| Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission (NCT00761579) | Janssen Korea, Ltd., Korea | 2008-04-01 |
| Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants (NCT00784238) | Janssen Korea, Ltd., Korea | 2008-04-01 |
| Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics (NCT00689325) | AstraZeneca | 2008-04-01 |
| Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia (NCT00645944) | Yale University | 2008-04-01 |
| Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function (NCT00645580) | Sha'ar Menashe Mental Health Center | 2008-04-01 |
| Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia (NCT00669903) | AstraZeneca | 2008-04-01 |
| Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants (NCT00761605) | Janssen Korea, Ltd., Korea | 2008-04-01 |
| Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia (NCT01915017) | The University of Texas Health Science Center at San Antonio | 2008-04-01 |
| Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill (NCT00809770) | University of Washington | 2008-04-01 |
| Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients (NCT00780884) | HaEmek Medical Center, Israel | 2008-04-01 |
| Genetics of Schizophrenia (NCT00619437) | Sheba Medical Center | 2008-04-01 |
| Safety and Tolerability of Varenicline in Schizophrenia (SATOVA) (NCT00702793) | University of British Columbia | 2008-04-01 |
| Cardio Risk of Acute Schizophrenia Olanzapine Duke (NCT00672464) | Duke University | 2008-04-01 |
| Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia (NCT00862992) | Tanabe Pharma Corporation | 2008-04-01 |